Top

Published in:

01-03-2022 | SARS-CoV-2 | COMMENTARY

COVID-19 and cancer: start the resolution!

Authors: Chantal Barksdale, Franciele C. Kipper, Shreya Tripathy, Selvakumar Subbian, Charles N. Serhan, Dipak Panigrahy

Published in: Cancer and Metastasis Reviews | Issue 1/2022

Abstract

Coronavirus disease 2019 (COVID-19) due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been an ongoing pandemic causing significant morbidity and mortality worldwide. The “cytokine storm” is a critical driving force in severe COVID-19 cases, leading to hyperinflammation, multi-system organ failure, and death. A paradigm shift is emerging in our understanding of the resolution of inflammation from a passive course to an active biochemical process driven by endogenous specialized pro-resolving mediators (SPMs), such as resolvins, protectins, lipoxins, and maresins. SPMs stimulate macrophage-mediated debris clearance and counter pro-inflammatory cytokine production, a process collectively termed as the “resolution of inflammation.” Hyperinflammation is not unique to COVID-19 and also occurs in neoplastic conditions, putting individuals with underlying health conditions such as cancer at elevated risk of severe SARS-CoV-2 infection. Despite approaches to block systemic inflammation, there are no current therapies designed to stimulate the resolution of inflammation in patients with COVID-19 or cancer. A non-immunosuppressive therapeutic approach that reduces the cytokine storm in patients with COVID-19 and cancer is urgently needed. SPMs are potent immunoresolvent and organ-protective lipid autacoids that stimulate the resolution of inflammation, facilitate clearance of infections, reduce thrombus burden, and promote a return to tissue homeostasis. Targeting endogenous lipid mediators, such as SPMs, offers an entirely novel approach to control SARS-CoV-2 infection and cancer by increasing the body’s natural reserve of pro-resolving mediators without overt toxicity or immunosuppression.

Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., Manson, J. J., Hlh Across Speciality Collaboration UK. (2020). COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet, 395(10229), 1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0CrossRefPubMedPubMedCentral

Serhan, C. N. (2014). Pro-resolving lipid mediators are leads for resolution physiology. Nature, 510(7503), 92–101. https://doi.org/10.1038/nature13479CrossRefPubMedPubMedCentral

Takeuchi, O., & Akira, S. (2010). Pattern recognition receptors and inflammation. Cell, 140(6), 805–820. https://doi.org/10.1016/j.cell.2010.01.022CrossRefPubMed

Roh, J. S., & Sohn, D. H. (2018). Damage-associated molecular patterns in inflammatory diseases. Immune Netw, 18(4), e27. https://doi.org/10.4110/in.2018.18.e27CrossRefPubMedPubMedCentral

Ricciotti, E., & FitzGerald, G. A. (2011). Prostaglandins and inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(5), 986–1000. https://doi.org/10.1161/ATVBAHA.110.207449CrossRefPubMedPubMedCentral

Conti, P., Caraffa, A., Gallenga, C. E., Ross, R., Kritas, S. K., Frydas, I., & Toniato, E. (2020). IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: Inhibitory effect of the IL-1 receptor antagonist (IL-1Ra). J Biol Regul Homeost Agents, 34(5), 1623–1627. https://doi.org/10.23812/20-34-4EDIT-65CrossRefPubMed

Pober, J. S., & Sessa, W. C. (2014). Inflammation and the blood microvascular system. Cold Spring Harbor Perspectives in Biology, 7(1), a016345. https://doi.org/10.1101/cshperspect.a016345CrossRefPubMed

Proost, P., Wuyts, A., & van Damme, J. (1996). The role of chemokines in inflammation. International Journal of Clinical and Laboratory Research, 26(4), 211–223. https://doi.org/10.1007/BF02602952CrossRefPubMed

Schultz, M. (2008). Rudolf Virchow. Emerging Infectious Diseases, 14(9), 1480–1481.CrossRefPubMedCentral

10.

Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008). Resolving inflammation: Dual anti-inflammatory and pro-resolution lipid mediators. Nature Reviews Immunology, 8(5), 349–361. https://doi.org/10.1038/nri2294CrossRefPubMedPubMedCentral

11.

Nathan, C., & Ding, A. (2010). Nonresolving inflammation. Cell, 140(6), 871–882. https://doi.org/10.1016/j.cell.2010.02.029CrossRefPubMed

12.

Fung, S. Y., Yuen, K. S., Ye, Z. W., Chan, C. P., & Jin, D. Y. (2020). A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: Lessons from other pathogenic viruses. Emerg Microbes Infect, 9(1), 558–570. https://doi.org/10.1080/22221751.2020.1736644CrossRefPubMed

13.

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan China. Lancet, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5CrossRefPubMedPubMedCentral

14.

Pedersen, S. F., & Ho, Y.-C. (2020). SARS-CoV-2: A storm is raging. The Journal of Clinical Investigation, 130(5), 2202–2205. https://doi.org/10.1172/JCI137647CrossRefPubMedPubMedCentral

15.

Ye, Q., Wang, B., & Mao, J. (2020). The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. The Journal of Infection, 80(6), 607–613. https://doi.org/10.1016/j.jinf.2020.03.037CrossRefPubMedPubMedCentral

16.

Panigrahy, D., Gilligan, M. M., Huang, S., Gartung, A., Cortes-Puch, I., Sime, P. J., & Hammock, B. D. (2020). Inflammation resolution: A dual-pronged approach to averting cytokine storms in COVID-19? Cancer and Metastasis Reviews, 39(2), 337–340. https://doi.org/10.1007/s10555-020-09889-4CrossRefPubMed

17.

Serhan, C. N., & Savill, J. (2005). Resolution of inflammation: The beginning programs the end. Nature Immunology, 6(12), 1191–1197. https://doi.org/10.1038/ni1276CrossRefPubMed

18.

Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10(3), 181–193. https://doi.org/10.1038/nrc2809CrossRefPubMedPubMedCentral

19.

Greene, E. R., Huang, S., Serhan, C. N., & Panigrahy, D. (2011). Regulation of inflammation in cancer by eicosanoids. Prostaglandins & Other Lipid Mediators, 96(1–4), 27–36. https://doi.org/10.1016/j.prostaglandins.2011.08.004CrossRef

20.

Sulciner, M. L., Gartung, A., Gilligan, M. M., Serhan, C. N., & Panigrahy, D. (2018). Targeting lipid mediators in cancer biology. Cancer Metastasis Reviews, 37(2–3), 557–572. https://doi.org/10.1007/s10555-018-9754-9CrossRefPubMed

21.

Serhan, C. N., Clish, C. B., Brannon, J., Colgan, S. P., Chiang, N., & Gronert, K. (2000). Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. Journal of Experimental Medicine, 192(8), 1197–1204. https://doi.org/10.1084/jem.192.8.1197CrossRefPubMedPubMedCentral

22.

Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R. L. (2002). Resolvins: A family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. Journal of Experimental Medicine, 196(8), 1025–1037. https://doi.org/10.1084/jem.20020760CrossRefPubMedPubMedCentral

23.

Chiang, N., & Serhan, C. N. (2020). Specialized pro-resolving mediator network: An update on production and actions. Essays in Biochemistry, 64(3), 443–462. https://doi.org/10.1042/EBC20200018CrossRefPubMedPubMedCentral

24.

Serhan, C. N. (2011). The resolution of inflammation: The devil in the flask and in the details. The FASEB Journal, 25(5), 1441–1448. https://doi.org/10.1096/fj.11-0502ufmCrossRefPubMedPubMedCentral

25.

Dalli, J., Chiang, N., & Serhan, C. N. (2015). Elucidation of novel 13-series resolvins that increase with atorvastatin and clear infections. Nature Medicine, 21(9), 1071–1075. https://doi.org/10.1038/nm.3911CrossRefPubMedPubMedCentral

26.

Oh, S. F., Pillai, P. S., Recchiuti, A., Yang, R., & Serhan, C. N. (2011). Pro-resolving actions and stereoselective biosynthesis of 18S E-series resolvins in human leukocytes and murine inflammation. The Journal of Clinical Investigation, 121(2), 569–581. https://doi.org/10.1172/JCI42545CrossRefPubMedPubMedCentral

27.

Bazan, N. G., Eady, T. N., Khoutorova, L., Atkins, K. D., Hong, S., Lu, Y., & Belayev, L. (2012). Novel aspirin-triggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke. Experimental Neurology, 236(1), 122–130. https://doi.org/10.1016/j.expneurol.2012.04.007CrossRefPubMedPubMedCentral

28.

Serhan, C. N., Fredman, G., Yang, R., Karamnov, S., Belayev, L. S., Bazan, N. G., & Petasis, N. A. (2011). Novel proresolving aspirin-triggered DHA pathway. Chemistry & Biology, 18(8), 976–987. https://doi.org/10.1016/j.chembiol.2011.06.008CrossRef

29.

Sun, Y. P., Oh, S. F., Uddin, J., Yang, R., Gotlinger, K., Campbell, E., & Serhan, C. N. (2007). Resolvin D1 and its aspirin-triggered 17R epimer Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J Biol Chem, 282(13), 9323–9334. https://doi.org/10.1074/jbc.M609212200CrossRefPubMed

30.

Dalli, J., Winkler, J. W., Colas, R. A., Arnardottir, H., Cheng, C. Y., Chiang, N., & Serhan, C. N. (2013). Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chemistry & Biology, 20(2), 188–201. https://doi.org/10.1016/j.chembiol.2012.11.010CrossRef

31.

Colas, R. A., Nhat, L. T. H., Thuong, N. T. T., Gomez, E. A., Ly, L., Thanh, H. H., & Dalli, J. (2019). Proresolving mediator profiles in cerebrospinal fluid are linked with disease severity and outcome in adults with tuberculous meningitis. The FASEB Journal, 33(11), 13028–13039. https://doi.org/10.1096/fj.201901590RCrossRefPubMedPubMedCentral

32.

Kooij, G., Troletti, C. D., Leuti, A., Norris, P. C., Riley, I., Albanese, M., & Chiurchiu, V. (2020). Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. Haematologica, 105(8), 2056–2070. https://doi.org/10.3324/haematol.2019.219519CrossRefPubMedPubMedCentral

33.

Sano, Y., Toyoshima, S., Miki, Y., Taketomi, Y., Ito, M., Lee, H., & Okayama, Y. (2020). Activation of inflammation and resolution pathways of lipid mediators in synovial fluid from patients with severe rheumatoid arthritis compared with severe osteoarthritis. Asia Pacific Allergy, 10(2), e21. https://doi.org/10.5415/apallergy.2020.10.e21CrossRefPubMedPubMedCentral

34.

Serhan, C. N., & Levy, B. D. (2018). Resolvins in inflammation: Emergence of the pro-resolving superfamily of mediators. The Journal of Clinical Investigation, 128(7), 2657–2669. https://doi.org/10.1172/JCI97943CrossRefPubMedPubMedCentral

35.

Chiang, N., & Serhan, C. N. (2017). Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors. Molecular Aspects of Medicine, 58, 114–129. https://doi.org/10.1016/j.mam.2017.03.005CrossRefPubMedPubMedCentral

36.

Serhan, C. N., Brain, S. D., Buckley, C. D., Gilroy, D. W., Haslett, C., O’Neill, L. A., & Wallace, J. L. (2007). Resolution of inflammation: State of the art, definitions and terms. The FASEB Journal, 21(2), 325–332. https://doi.org/10.1096/fj.06-7227revCrossRefPubMed

37.

Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., & Wang, F.-S. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet. Respiratory Medicine, 8(4), 420–422. https://doi.org/10.1016/S2213-2600(20)30076-XCrossRefPubMedPubMedCentral

38.

Azkur, A. K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.-C., & Akdis, C. A. (2020). Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy, 75(7), 1564–1581. https://doi.org/10.1111/all.14364CrossRefPubMed

39.

Gartung, A., Yang, J., Sukhatme, V. P., Bielenberg, D. R., Fernandes, D., Chang, J., & Panigrahy, D. (2019). Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 116(5), 1698–1703. https://doi.org/10.1073/pnas.1803999116CrossRefPubMedPubMedCentral

40.

Fishbein, A., Wang, W., Yang, H., Yang, J., Hallisey, V. M., Deng, J., & Panigrahy, D. (2020). Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 117(35), 21576–21587. https://doi.org/10.1073/pnas.2007412117CrossRefPubMedPubMedCentral

41.

Godfred-Cato, S., Bryant, B., Leung, J., Oster, M. E., Conklin, L., Abrams, J., California MIS-C Response Team. (2020). COVID-19–associated multisystem inflammatory syndrome in children — United States, March–July 2020. MMWR. Morbidity and Mortality Weekly Report, 69(32), 1074–1080. https://doi.org/10.15585/mmwr.mm6932e2CrossRefPubMedPubMedCentral

42.

Hue, S., Beldi-Ferchiou, A., Bendib, I., Surenaud, M., Fourati, S., Frapard, T., & de Prost, N. (2020). Uncontrolled innate and impaired adaptive immune responses in patients with COVID-19 acute respiratory distress syndrome. American Journal of Respiratory and Critical Care Medicine, 202(11), 1509–1519. https://doi.org/10.1164/rccm.202005-1885OCCrossRefPubMedPubMedCentral

43.

WHO Coronavirus (COVID-19) Dashboard. (2021). World Health Organization. Retrieved from https://covid19.who.int/

44.

Wong, C. K., Lam, C. W., Wu, A. K., Ip, W. K., Lee, N. L., Chan, I. H., & Sung, J. J. (2004). Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clinical and Experimental Immunology, 136(1), 95–103. https://doi.org/10.1111/j.1365-2249.2004.02415.xCrossRefPubMedPubMedCentral

45.

Zhang, Y., Li, J., Zhan, Y., Wu, L., Yu, X., Zhang, W., & Lou, J. (2004). Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infection and Immunity, 72(8), 4410–4415. https://doi.org/10.1128/IAI.72.8.4410-4415.2004CrossRefPubMedPubMedCentral

46.

Chien, J. Y., Hsueh, P. R., Cheng, W. C., Yu, C. J., & Yang, P. C. (2006). Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. Respirology, 11(6), 715–722. https://doi.org/10.1111/j.1440-1843.2006.00942.xCrossRefPubMedPubMedCentral

47.

Aksakal, A., Kerget, B., Kerget, F., & Askin, S. (2021). Evaluation of the relationship between macrophage migration inhibitory factor level and clinical course in patients with COVID-19 pneumonia. Journal of Medical Virology, 93(12), 6519–6524. https://doi.org/10.1002/jmv.27189CrossRefPubMed

48.

Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., & Ning, Q. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation, 130(5), 2620–2629. https://doi.org/10.1172/JCI137244CrossRefPubMedPubMedCentral

49.

Sivakorn, C., Dechsanga, J., Jamjumrus, L., Boonnak, K., Schultz, M. J., Dorndorp, A. M., & Techarang, T. (2021). High mobility group box 1 and interleukin 6 at intensive care unit admission as biomarkers in critically ill COVID-19 patients. American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.21-0165CrossRefPubMedPubMedCentral

50.

Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan. China. Intensive Care Med, 46(5), 846–848. https://doi.org/10.1007/s00134-020-05991-xCrossRefPubMed

51.

Cuesta-Llavona, E., Gomez, J., Albaiceta, G. M., Amado-Rodriguez, L., Garcia-Clemente, M., Gutierrez-Rodriguez, J., & Coto, E. (2021). Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity. International Immunopharmacology, 98, 107825. https://doi.org/10.1016/j.intimp.2021.107825CrossRefPubMedPubMedCentral

52.

Winkler, E. S., Bailey, A. L., Kafai, N. M., Nair, S., McCune, B. T., Yu, J., & Diamond, M. S. (2020). SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nature Immunology, 21(11), 1327–1335. https://doi.org/10.1038/s41590-020-0778-2CrossRefPubMedPubMedCentral

53.

Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, tenOever BR. (2020). Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell, 181(5), 1036–1045 e9. https://doi.org/10.1016/j.cell.2020.04.026

54.

Abdelmoaty, M. M., Yeapuri, P., Machhi, J., Olson, K. E., Shahjin, F., Kumar, V., & Gendelman, H. E. (2021). Defining the innate immune responses for SARS-CoV-2-human macrophage interactions. Frontiers in Immunology, 12, 741502. https://doi.org/10.3389/fimmu.2021.741502CrossRefPubMedPubMedCentral

55.

Urano, E., Okamura, T., Ono, C., Ueno, S., Nagata, S., Kamada, H., & Yasutomi, Y. (2021). COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions. Proceedings of the National Academy of Sciences, 118(43), e2104847118. https://doi.org/10.1073/pnas.2104847118CrossRef

56.

Smits, S. L., de Lang, A., van den Brand, J. M., Leijten, L. M., van Ij, W. F., Eijkemans, M. J., & Haagmans, B. L. (2010). Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog, 6(2), e1000756. https://doi.org/10.1371/journal.ppat.1000756CrossRefPubMedPubMedCentral

57.

Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Casanova JL (2020). Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 370(6515) https://doi.org/10.1126/science.abd4585

58.

Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Casanova JL (2020). Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 370(6515). https://doi.org/10.1126/science.abd4570

59.

Ramasamy, S., & Subbian, S. (2021). Critical determinants of cytokine storm and type i interferon response in COVID-19 pathogenesis. Clinical Microbiology Reviews, 34(3), e00299-e320. https://doi.org/10.1128/CMR.00299-20CrossRefPubMedPubMedCentral

60.

Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020). Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, 181(2), 281-292.e6. https://doi.org/10.1016/j.cell.2020.02.058CrossRefPubMedPubMedCentral

61.

Versteeg, G. A., van de Nes, P. S., Bredenbeek, P. J., & Spaan, W. J. (2007). The coronavirus spike protein induces endoplasmic reticulum stress and upregulation of intracellular chemokine mRNA concentrations. Journal of Virology, 81(20), 10981–10990. https://doi.org/10.1128/JVI.01033-07CrossRefPubMedPubMedCentral

62.

Aoe, T. (2020). Pathological aspects of COVID-19 as a conformational disease and the use of pharmacological chaperones as a potential therapeutic strategy. Frontiers in Pharmacology, 11, 1095. https://doi.org/10.3389/fphar.2020.01095CrossRefPubMedPubMedCentral

63.

Shaban, M. S., Müller, C., Mayr-Buro, C., Weiser, H., Meier-Soelch, J., Albert, B. V., & Kracht, M. (2021). Multi-level inhibition of coronavirus replication by chemical ER stress. Nature Communications, 12(1), 5536. https://doi.org/10.1038/s41467-021-25551-1CrossRefPubMedPubMedCentral

64.

Fung, T. S., Huang, M., & Liu, D. X. (2014). Coronavirus-induced ER stress response and its involvement in regulation of coronavirus-host interactions. Virus Research, 194, 110–123. https://doi.org/10.1016/j.virusres.2014.09.016CrossRefPubMedPubMedCentral

65.

Li, S., Zhang, Y., Guan, Z., Li, H., Ye, M., Chen, X., & Peng, K. (2020). SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduction and Targeted Therapy, 5(1), 235. https://doi.org/10.1038/s41392-020-00334-0CrossRefPubMedPubMedCentral

66.

Ren, Y., Shu, T., Wu, D., Mu, J., Wang, C., Huang, M., & Zhou, X. (2020). The ORF3a protein of SARS-CoV-2 induces apoptosis in cells. Cellular & Molecular Immunology, 17(8), 881–883. https://doi.org/10.1038/s41423-020-0485-9CrossRef

67.

Gradin, A., Andersson, H., Luther, T., Anderberg, S. B., Rubertsson, S., Lipcsey, M., & Hultstrom, M. (2021). Urinary cytokines correlate with acute kidney injury in critically ill COVID-19 patients. Cytokine, 146, 155589. https://doi.org/10.1016/j.cyto.2021.155589CrossRefPubMedPubMedCentral

68.

Trypsteen, W., Van Cleemput, J., van Snippenberg, W., Gerlo, S., & Vandekerckhove, L. (2020). On the whereabouts of SARS-CoV-2 in the human body: A systematic review. PLOS Pathogens, 16(10), e1009037. https://doi.org/10.1371/journal.ppat.1009037CrossRefPubMedPubMedCentral

69.

Chua, R. L., Lukassen, S., Trump, S., Hennig, B. P., Wendisch, D., Pott, F., & Eils, R. (2020). COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis. Nature Biotechnology, 38(8), 970–979. https://doi.org/10.1038/s41587-020-0602-4CrossRefPubMed

70.

DeBiasi, R. L., Harahsheh, A. S., Srinivasalu, H., Krishnan, A., Sharron, M. P., Parikh, K., Children’s National Hospital MISCT. (2021). Multisystem inflammatory syndrome of children: Subphenotypes, risk factors, biomarkers, cytokine profiles, and viral sequencing. Journal of Pediatrics, 237(125–135), e18. https://doi.org/10.1016/j.jpeds.2021.06.002CrossRef

71.

Koenis, D. S., Beegun, I., Jouvene, C. C., Aguirre, G. A., Souza, P. R., Gonzalez-Nunez, M., & Dalli, J. (2021). Disrupted resolution mechanisms favor altered phagocyte responses in COVID-19. Circulation Research, 129(4), e54–e71. https://doi.org/10.1161/CIRCRESAHA.121.319142CrossRefPubMedPubMedCentral

72.

Palmas, F., Clarke, J., Colas, R. A., Gomez, E. A., Keogh, A., Boylan, M., & Dalli, J. (2021). Dysregulated plasma lipid mediator profiles in critically ill COVID-19 patients. PLoS ONE, 16(8), e0256226. https://doi.org/10.1371/journal.pone.0256226CrossRefPubMedPubMedCentral

73.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013CrossRefPubMed

74.

Taniguchi, K., & Karin, M. (2018). NF-κB, inflammation, immunity and cancer: Coming of age. Nature Reviews Immunology, 18(5), 309–324. https://doi.org/10.1038/nri.2017.142CrossRefPubMed

75.

Maeda, H., & Akaike, T. (1998). Nitric oxide and oxygen radicals in infection, inflammation, and cancer. Biochemistry (Moscow), 63(7), 854–865.

76.

Agarwal, S., Reddy, G. V., & Reddanna, P. (2009). Eicosanoids in inflammation and cancer: The role of COX-2. Expert Review of Clinical Immunology, 5(2), 145–165. https://doi.org/10.1586/1744666X.5.2.145CrossRefPubMed

77.

Dvorak, H. F. (1986). Tumors: Wounds that do not heal Similarities between tumor stroma generation and wound healing. N Engl J Med, 315(26), 1650–9. https://doi.org/10.1056/NEJM198612253152606CrossRefPubMed

78.

DeNardo, D. G., Andreu, P., & Coussens, L. M. (2010). Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity. Cancer and Metastasis Reviews, 29(2), 309–316. https://doi.org/10.1007/s10555-010-9223-6CrossRefPubMed

79.

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883–899. https://doi.org/10.1016/j.cell.2010.01.025CrossRefPubMedPubMedCentral

80.

Qian, B. Z., & Pollard, J. W. (2010). Macrophage diversity enhances tumor progression and metastasis. Cell, 141(1), 39–51. https://doi.org/10.1016/j.cell.2010.03.014CrossRefPubMedPubMedCentral

81.

Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009). Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis, 30(7), 1073–1081. https://doi.org/10.1093/carcin/bgp127CrossRefPubMed

82.

Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454(7203), 436–444. https://doi.org/10.1038/nature07205CrossRefPubMed

83.

Chang, J., Bhasin, S. S., Bielenberg, D. R., Sukhatme, V. P., Bhasin, M., Huang, S., & Panigrahy, D. (2019). Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin. FASEB journal: Official publication of the Federation of American Societies for Experimental Biology, 33(1), 114–125. https://doi.org/10.1096/fj.201800019RRCrossRef

84.

Sulciner, M. L., Serhan, C. N., Gilligan, M. M., Mudge, D. K., Chang, J., Gartung, A., & Panigrahy, D. (2018). Resolvins suppress tumor growth and enhance cancer therapy. Journal of Experimental Medicine, 215(1), 115–140. https://doi.org/10.1084/jem.20170681CrossRefPubMedPubMedCentral

85.

Fishbein, A., Hammock, B. D., Serhan, C. N., & Panigrahy, D. (2021). Carcinogenesis: Failure of resolution of inflammation? Pharmacology & Therapeutics, 218, 107670. https://doi.org/10.1016/j.pharmthera.2020.107670CrossRef

86.

Haak, V. M., Huang, S., & Panigrahy, D. (2021). Debris-stimulated tumor growth: A Pandora’s box? Cancer Metastasis Reviews, 40(3), 791–801. https://doi.org/10.1007/s10555-021-09998-8CrossRefPubMedPubMedCentral

87.

Deng, J., Yang, H., Haak, V. M., Yang, J., Kipper, F. C., Barksdale, C., & Panigrahy, D. (2021). Eicosanoid regulation of debris-stimulated metastasis. Proceedings of the National Academy of Sciences of the United States of America, 118(41), e2107771118. https://doi.org/10.1073/pnas.2107771118CrossRefPubMedPubMedCentral

88.

Coussens, L. M., & Werb, Z. (2002). Inflammation and cancer. Nature, 420(6917), 860–867. https://doi.org/10.1038/nature01322CrossRefPubMedPubMedCentral

89.

Landskron, G., De la Fuente, M., Thuwajit, P., Thuwajit, C., & Hermoso, M. A. (2014). Chronic inflammation and cytokines in the tumor microenvironment. Journal of Immunology Research, 2014, 1–19. https://doi.org/10.1155/2014/149185CrossRef

90.

Torisu, H., Ono, M., Kiryu, H., Furue, M., Ohmoto, Y., Nakayama, J., & Kuwano, M. (2000). Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFalpha and IL-1alpha. International Journal of Cancer, 85(2), 182–188.CrossRefPubMed

91.

Shang, G. S., Liu, L., & Qin, Y. W. (2017). IL-6 and TNF-alpha promote metastasis of lung cancer by inducing epithelial-mesenchymal transition. Oncology Letters, 13(6), 4657–4660. https://doi.org/10.3892/ol.2017.6048CrossRefPubMedPubMedCentral

92.

Ridker, P. M., MacFadyen, J. G., Thuren, T., Everett, B. M., Libby, P., Glynn, R. J., Group CT. (2017). Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, 390(10105), 1833–1842. https://doi.org/10.1016/S0140-6736(17)32247-XCrossRefPubMed

93.

Zlotnik, A., Burkhardt, A. M., & Homey, B. (2011). Homeostatic chemokine receptors and organ-specific metastasis. Nature Reviews Immunology, 11(9), 597–606. https://doi.org/10.1038/nri3049CrossRefPubMed

94.

Wiley, H. E., Gonzalez, E. B., Maki, W., Wu, M. T., & Hwang, S. T. (2001). Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. Journal of the National Cancer Institute, 93(21), 1638–1643. https://doi.org/10.1093/jnci/93.21.1638CrossRefPubMed

95.

Murakami, T., Maki, W., Cardones, A. R., Fang, H., Tun Kyi, A., Nestle, F. O., & Hwang, S. T. (2002). Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Research, 62(24), 7328–7334.PubMed

96.

Keith, R. L., Geraci, M. W., Nana-Sinkam, S. P., Breyer, R. M., Hudish, T. M., Meyer, A. M., & Dwyer-Nield, L. D. (2006). Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis. Anticancer Research, 26(4B), 2857–2861.PubMed

97.

Bonavita, E., Pelly, V. S., & Zelenay, S. (2018). Resolving the dark side of therapy-driven cancer cell death. The Journal of Experimental Medicine, 215(1), 9–11. https://doi.org/10.1084/jem.20172044CrossRefPubMedPubMedCentral

98.

Revesz, L. (1956). Effect of tumour cells killed by x-rays upon the growth of admixed viable cells. Nature, 178(4547), 1391–1392. https://doi.org/10.1038/1781391a0CrossRefPubMed

99.

Huang, Q., Li, F., Liu, X., Li, W., Shi, W., Liu, F. F., & Li, C. Y. (2011). Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy. Nature Medicine, 17(7), 860–866. https://doi.org/10.1038/nm.2385CrossRefPubMedPubMedCentral

100.

Chaurio, R., Janko, C., Schorn, C., Maueröder, C., Bilyy, R., Gaipl, U., & Munoz, L. E. (2013). UVB-irradiated apoptotic cells induce accelerated growth of co-implanted viable tumor cells in immune competent mice. Autoimmunity, 46(5), 317–322. https://doi.org/10.3109/08916934.2012.754433CrossRefPubMed

101.

Correa, M., Machado, J., Jr., Carneiro, C. R., Pesquero, J. B., Bader, M., Travassos, L. R., & Jasiulionis, M. G. (2005). Transient inflammatory response induced by apoptotic cells is an important mediator of melanoma cell engraftment and growth. International Journal of Cancer, 114(3), 356–363. https://doi.org/10.1002/ijc.20673CrossRefPubMed

102.

Ford, C. A., Petrova, S., Pound, J. D., Voss, J. J., Melville, L., Paterson, M., & Gregory, C. D. (2015). Oncogenic properties of apoptotic tumor cells in aggressive B cell lymphoma. Current Biology, 25(5), 577–588. https://doi.org/10.1016/j.cub.2014.12.059CrossRefPubMedPubMedCentral

103.

Zimmerman, M. A., Huang, Q., Li, F., Liu, X., & Li, C. Y. (2013). Cell death-stimulated cell proliferation: A tissue regeneration mechanism usurped by tumors during radiotherapy. Semin Radiat Oncol, 23(4), 288–295. https://doi.org/10.1016/j.semradonc.2013.05.003CrossRefPubMedPubMedCentral

104.

de Jong, J. S., van Diest, P. J., & Baak, J. P. (2000). Number of apoptotic cells as a prognostic marker in invasive breast cancer. British Journal of Cancer, 82(2), 368–373. https://doi.org/10.1054/bjoc.1999.0928CrossRefPubMedPubMedCentral

105.

Sun, B., Sun, Y., Wang, J., Zhao, X., Wang, X., & Hao, X. (2006). Extent, relationship and prognostic significance of apoptosis and cell proliferation in synovial sarcoma. European journal of cancer prevention: The official journal of the European Cancer Prevention Organisation (ECP), 15(3), 258–265. https://doi.org/10.1097/01.cej.0000198896.02185.68CrossRef

106.

Gregory, C. D., & Pound, J. D. (2011). Cell death in the neighbourhood: Direct microenvironmental effects of apoptosis in normal and neoplastic tissues. The Journal of Pathology, 223(2), 177–194. https://doi.org/10.1002/path.2792CrossRefPubMed

107.

Naresh, K. N., Lakshminarayanan, K., Pai, S. A., & Borges, A. M. (2001). Apoptosis index is a predictor of metastatic phenotype in patients with early stage squamous carcinoma of the tongue: A hypothesis to support this paradoxical association. Cancer, 91(3), 578–584.CrossRefPubMed

108.

Jalalinadoushan, M., Peivareh, H., & Azizzadeh Delshad, A. (2004). Correlation between apoptosis and histological grade of transitional cell carcinoma of urinary bladder. Urology Journal, 1(3), 177–179.PubMed

109.

Filippou, P. S., & Karagiannis, G. S. (2020). Cytokine storm during chemotherapy: A new companion diagnostic emerges? Oncotarget, 11(3), 213–215. https://doi.org/10.18632/oncotarget.27442CrossRefPubMedPubMedCentral

110.

Majno G. ; J I. (2004). Cells, tissues and disease: Principles of general pathology (2nd ed.). Oxford University Press.

111.

Rainsford, K. D. (2007). Anti-inflammatory drugs in the 21st century. SubCellular Biochemistry, 42, 3–27. https://doi.org/10.1007/1-4020-5688-5_1CrossRefPubMed

112.

Sneader, W. (2000). The discovery of aspirin: A reappraisal. BMJ, 321(7276), 1591–1594. https://doi.org/10.1136/bmj.321.7276.1591CrossRefPubMedPubMedCentral

113.

Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature: New Biology, 231(25), 232–235. https://doi.org/10.1038/newbio231232a0CrossRef

114.

Vane, J. R., & Botting, R. M. (2003). The mechanism of action of aspirin. Thrombosis Research, 110(5–6), 255–258. https://doi.org/10.1016/S0049-3848(03)00379-7CrossRefPubMed

115.

Panigrahy, D., Gilligan, M. M., Serhan, C. N., & Kashfi, K. (2021). Resolution of inflammation: An organizing principle in biology and medicine. Pharmacology & Therapeutics, 227, 107879. https://doi.org/10.1016/j.pharmthera.2021.107879CrossRef

116.

Ripon, M. A. R., Bhowmik, D. R., Amin, M. T., & Hossain, M. S. (2021). Role of arachidonic cascade in COVID-19 infection: A review. Prostaglandins & Other Lipid Mediators, 154, 106539. https://doi.org/10.1016/j.prostaglandins.2021.106539CrossRef

117.

Noreen, S., Maqbool, I., & Madni, A. (2021). Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic. European Journal of Pharmacology, 894, 173854. https://doi.org/10.1016/j.ejphar.2021.173854CrossRefPubMedPubMedCentral

118.

Zentay, Z., Sharaf, M., Qadir, M., Drafta, D., & Davidson, D. (1999). Mechanism for dexamethasone inhibition of neutrophil migration upon exposure to lipopolysaccharide in vitro: Role of neutrophil interleukin-8 release. Pediatric Research, 46(4), 406–410. https://doi.org/10.1203/00006450-199910000-00008CrossRefPubMed

119.

Group WHOREA for C-19 TW, Sterne, J. A. C., Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., & Marshall, J. C. (2020). Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA, 324(13), 1330–1341. https://doi.org/10.1001/jama.2020.17023CrossRef

120.

Youssef, J., Novosad, S. A., & Winthrop, K. L. (2016). Infection risk and safety of corticosteroid use. Rheumatic Disease Clinics of North America, 42(1), 157–176. https://doi.org/10.1016/j.rdc.2015.08.004CrossRefPubMed

121.

Rosas, I. O., Bräu, N., Waters, M., Go, R. C., Hunter, B. D., Bhagani, S., & Malhotra, A. (2021). Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. New England Journal of Medicine, 384(16), 1503–1516. https://doi.org/10.1056/NEJMoa2028700CrossRefPubMed

122.

Lescure, F.-X., Honda, H., Fowler, R. A., Lazar, J. S., Shi, G., Wung, P., & Vizcarra, P. (2021). Sarilumab in patients admitted to hospital with severe or critical COVID-19: A randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Respiratory Medicine, 9(5), 522–532. https://doi.org/10.1016/S2213-2600(21)00099-0CrossRefPubMedPubMedCentral

123.

Group W. H. O. R. E. A. for C-19 TW, Shankar-Hari, M., Vale, C. L., Godolphin, P. J., Fisher, D., Higgins, J. P. T., & Sterne, J. A. C. (2021). Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A Meta-analysis. JAMA, 326(6), 499–518. https://doi.org/10.1001/jama.2021.11330CrossRef

124.

Gopalaswamy, R., & Subbian, S. (2021). Corticosteroids for COVID-19 therapy: Potential implications on tuberculosis. International Journal of Molecular Sciences, 22(7), 3773. https://doi.org/10.3390/ijms22073773CrossRefPubMedPubMedCentral

125.

Hou, J., Karin, M., & Sun, B. (2021). Targeting cancer-promoting inflammation - Have anti-inflammatory therapies come of age? Nature Reviews. Clinical Oncology, 18(5), 261–279. https://doi.org/10.1038/s41571-020-00459-9CrossRefPubMedPubMedCentral

126.

Zelenay, S., Veen van der, A. G., Bottcher, J. P., Snelgrove, K. J., Rogers, N., Acton, S. E., & Reis e Sousa, C. (2015). Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell, 162(6), 1257–70. https://doi.org/10.1016/j.cell.2015.08.015CrossRefPubMedPubMedCentral

127.

Cao, Y., Nishihara, R., Wu, K., Wang, M., Ogino, S., Willett, W. C., & Chan, A. T. (2016). Population-wide impact of long-term use of aspirin and the risk for cancer. JAMA Oncology, 2(6), 762–769. https://doi.org/10.1001/jamaoncol.2015.6396CrossRefPubMedPubMedCentral

128.

Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012). Effect of daily aspirin on risk of cancer metastasis: A study of incident cancers during randomised controlled trials. Lancet, 379(9826), 1591–1601. https://doi.org/10.1016/S0140-6736(12)60209-8CrossRefPubMed

129.

Desmedt, C., Demicheli, R., Fornili, M., Bachir, I., Duca, M., Viglietti, G., & Biganzoli, E. (2018). Potential benefit of intra-operative administration of ketorolac on breast cancer recurrence according to the patient’s body mass index. Journal of the National Cancer Institute, 110(10), 1115–1122. https://doi.org/10.1093/jnci/djy042CrossRefPubMed

130.

Frouws, M. A., Bastiaannet, E., Langley, R. E., Chia, W. K., van Herk-Sukel, M. P., Lemmens, V. E., & Liefers, G. J. (2017). Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study. British Journal of Cancer, 116(3), 405–413. https://doi.org/10.1038/bjc.2016.425CrossRefPubMedPubMedCentral

131.

Swiss Group for Clinical Cancer Research. (2021). Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial (clinical trial registration no. NCT02467582). clinicaltrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02467582

132.

Martling A (2021). A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signaling pathway (clinical trial registration no. NCT02647099). clinicaltrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02647099

133.

Kuang JCW (2021). Aspirin for dukes C and high risk dukes B colorectal cancers - An international, multi-center, double blind, randomized placebo controlled phase III trial (clinical trial registration no. NCT00565708). clinicaltrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT00565708

134.

GJLiefers. (2021). A phase III double-blind placebo-controlled randomised trial of aspirin on recurrence and survival in colon cancer patients (clinical trial registration no. NCT02301286). clinicaltrials.gov. Retrieved from https://clinicaltrials.gov/ct2/show/NCT02301286

135.

Hong, D. S., Hui, D., Bruera, E., Janku, F., Naing, A., Falchook, G. S., & Kurzrock, R. (2014). MABp1, a first-in-class true human antibody targeting interleukin-1alpha in refractory cancers: An open-label, phase 1 dose-escalation and expansion study. The lancet Oncology, 15(6), 656–666. https://doi.org/10.1016/S1470-2045(14)70155-XCrossRefPubMed

136.

Hickish, T., Andre, T., Wyrwicz, L., Saunders, M., Sarosiek, T., Kocsis, J., & de Gramont, A. (2017). MABp1 as a novel antibody treatment for advanced colorectal cancer: A randomised, double-blind, placebo-controlled, phase 3 study. The lancet Oncology, 18(2), 192–201. https://doi.org/10.1016/S1470-2045(17)30006-2CrossRefPubMed

137.

Shirmohammadi, E., Ebrahimi, S.-E.S., Farshchi, A., & Salimi, M. (2020). The efficacy of etanercept as anti-breast cancer treatment is attenuated by residing macrophages. BMC Cancer, 20(1), 836. https://doi.org/10.1186/s12885-020-07228-yCrossRefPubMedPubMedCentral

138.

Huang, D., Xue, J., Li, S., & Yang, D. (2018). Oxaliplatin and infliximab synergize to induce regression of colon cancer. Oncology Letters, 15(2), 1517–1522. https://doi.org/10.3892/ol.2017.7468CrossRefPubMed

139.

Mahady, S. E., Margolis, K. L., Chan, A., Polekhina, G., Woods, R. L., Wolfe, R., & McNeil, J. J. (2021). Major GI bleeding in older persons using aspirin: Incidence and risk factors in the ASPREE randomised controlled trial. Gut, 70(4), 717–724. https://doi.org/10.1136/gutjnl-2020-321585CrossRefPubMed

140.

Lo, P.-C., Tsai, Y.-T., Lin, S.-K., & Lai, J.-N. (2016). Risk of asthma exacerbation associated with nonsteroidal anti-inflammatory drugs in childhood asthma: A nationwide population-based cohort study in Taiwan. Medicine, 95(41), e5109. https://doi.org/10.1097/MD.0000000000005109CrossRefPubMedPubMedCentral

141.

Arber, N., Eagle, C. J., Spicak, J., Racz, I., Dite, P., Hajer, J., & Pre, S. A. P. T. I. (2006). Celecoxib for the prevention of colorectal adenomatous polyps. New England Journal of Medicine, 355(9), 885–895. https://doi.org/10.1056/NEJMoa061652CrossRefPubMed

142.

Bertagnolli, M. M., Eagle, C. J., Zauber, A. G., Redston, M., Solomon, S. D., Kim, K., & Investigators, A. P. C. S. (2006). Celecoxib for the prevention of sporadic colorectal adenomas. New England Journal of Medicine, 355(9), 873–884. https://doi.org/10.1056/NEJMoa061355CrossRefPubMed

143.

Baron, J. A., Sandler, R. S., Bresalier, R. S., Quan, H., Riddell, R., Lanas, A., Investigators, A., & Pprov, T. (2006). A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology, 131(6), 1674–82. https://doi.org/10.1053/j.gastro.2006.08.079CrossRefPubMed

144.

Serhan, C. N. (2017). Treating inflammation and infection in the 21st century: New hints from decoding resolution mediators and mechanisms. The FASEB Journal, 31(4), 1273–1288. https://doi.org/10.1096/fj.201601222RCrossRefPubMedPubMedCentral

145.

Andreakos, E., Papadaki, M., & Serhan, C. N. (2021). Dexamethasone, pro-resolving lipid mediators and resolution of inflammation in COVID-19. Allergy, 76(3), 626–628. https://doi.org/10.1111/all.14595CrossRefPubMed

146.

Pyrillou K, Chairakaki AD, Tamvakopoulos C & Andreakos E (2018) Dexamethasone induces omega3-derived immunoresolvents driving resolution of allergic airway inflammation. J Allergy Clin Immunol, 142(2), 691–695 e4. https://doi.org/10.1016/j.jaci.2018.04.004

147.

Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., & Serhan, C. N. (2001). Lipid mediator class switching during acute inflammation: Signals in resolution. Nature Immunology, 2(7), 612–619. https://doi.org/10.1038/89759CrossRefPubMed

148.

Sugimoto MA, Sousa LP, Pinho V, Perretti M, & Teixeira MM (2016). Resolution of inflammation: What controls its onset? Frontiers in Immunology, 7.https://doi.org/10.3389/fimmu.2016.00160

149.

Schwab, J. M., Chiang, N., Arita, M., & Serhan, C. N. (2007). Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature, 447(7146), 869–874. https://doi.org/10.1038/nature05877CrossRefPubMedPubMedCentral

150.

Chiurchiu, V., Leuti, A., Dalli, J., Jacobsson, A., Battistini, L., Maccarrone, M., & Serhan, C. N. (2016). Proresolving lipid mediators resolvin D1, resolvin D2, and maresin 1 are critical in modulating T cell responses. Sci Transl Med, 8(353), 353ra111. https://doi.org/10.1126/scitranslmed.aaf7483CrossRefPubMedPubMedCentral

151.

Archambault, A. S., Zaid, Y., Rakotoarivelo, V., Turcotte, C., Dore, E., Dubuc, I., & Flamand, N. (2021). High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. The FASEB Journal, 35(6), e21666. https://doi.org/10.1096/fj.202100540RCrossRefPubMedPubMedCentral

152.

Recchiuti, A., Patruno, S., Mattoscio, D., Isopi, E., Pomilio, A., Lamolinara, A., & Romano, M. (2021). Resolvin D1 and D2 reduce SARS-CoV-2-induced inflammatory responses in cystic fibrosis macrophages. The FASEB Journal, 35(4), e21441. https://doi.org/10.1096/fj.202001952RCrossRefPubMedPubMedCentral

153.

Morita, M., Kuba, K., Ichikawa, A., Nakayama, M., Katahira, J., Iwamoto, R., & Imai, Y. (2013). The lipid mediator protectin D1 inhibits influenza virus replication and improves severe influenza. Cell, 153(1), 112–125. https://doi.org/10.1016/j.cell.2013.02.027CrossRefPubMed

154.

Imai, Y. (2015). Role of omega-3 PUFA-derived mediators, the protectins, in influenza virus infection. Biochimica Et Biophysica Acta, 1851(4), 496–502. https://doi.org/10.1016/j.bbalip.2015.01.006CrossRefPubMed

155.

Tam, V. C., Quehenberger, O., Oshansky, C. M., Suen, R., Armando, A. M., Treuting, P. M., & Aderem, A. (2013). Lipidomic profiling of influenza infection identifies mediators that induce and resolve inflammation. Cell, 154(1), 213–227. https://doi.org/10.1016/j.cell.2013.05.052CrossRefPubMedPubMedCentral

156.

Tam, V. C. (2013). Lipidomic profiling of bioactive lipids by mass spectrometry during microbial infections. Seminars in Immunology, 25(3), 240–248. https://doi.org/10.1016/j.smim.2013.08.006CrossRefPubMed

157.

Rajasagi, N. K., Reddy, P. B., Suryawanshi, A., Mulik, S., Gjorstrup, P., & Rouse, B. T. (2011). Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1. The Journal of Immunology, 186(3), 1735–1746. https://doi.org/10.4049/jimmunol.1003456CrossRefPubMed

158.

Rajasagi, N. K., Reddy, P. B., Mulik, S., Gjorstrup, P., & Rouse, B. T. (2013). Neuroprotectin D1 reduces the severity of herpes simplex virus-induced corneal immunopathology. Investigative Ophthalmology & Visual Science, 54(9), 6269–6279. https://doi.org/10.1167/iovs.13-12152CrossRef

159.

Baillie, J. K., & Digard, P. (2013). Influenza-Time to target the host? The New England Journal of Medicine, 369(2), 191–193. https://doi.org/10.1056/NEJMcibr1304414CrossRefPubMed

160.

Wang, Q., Zheng, X., Cheng, Y., Zhang, Y. L., Wen, H. X., Tao, Z., & Jin, S. W. (2014). Resolvin D1 stimulates alveolar fluid clearance through alveolar epithelial sodium channel, Na, K-ATPase via ALX/cAMP/PI3K pathway in lipopolysaccharide-induced acute lung injury. The Journal of Immunology, 192(8), 3765–3777. https://doi.org/10.4049/jimmunol.1302421CrossRefPubMed

161.

Zhuo, X. J., Hao, Y., Cao, F., Yan, S. F., Li, H., Wang, Q., & Jin, S. W. (2018). Protectin DX increases alveolar fluid clearance in rats with lipopolysaccharide-induced acute lung injury. Experimental & Molecular Medicine, 50(4), 1–13. https://doi.org/10.1038/s12276-018-0075-4CrossRef

162.

Zhang, J. L., Zhuo, X. J., Lin, J., Luo, L. C., Ying, W. Y., Xie, X., & Jin, S. W. (2017). Maresin1 stimulates alveolar fluid clearance through the alveolar epithelial sodium channel Na, K-ATPase via the ALX/PI3K/Nedd4-2 pathway. Laboratory Investigation, 97(5), 543–554. https://doi.org/10.1038/labinvest.2016.150CrossRefPubMed

163.

Sekheri, M., El Kebir, D., Edner, N., & Filep, J. G. (2020). 15-Epi-LXA4 and 17-epi-RvD1 restore TLR9-mediated impaired neutrophil phagocytosis and accelerate resolution of lung inflammation. Proc Natl Acad Sci U S A, 117(14), 7971–7980. https://doi.org/10.1073/pnas.1920193117CrossRefPubMedPubMedCentral

164.

Sandhaus, S., & Swick, A. G. (2021). Specialized proresolving mediators in infection and lung injury. BioFactors, 47(1), 6–18. https://doi.org/10.1002/biof.1691CrossRefPubMed

165.

Nicolai, L., Leunig, A., Brambs, S., Kaiser, R., Weinberger, T., Weigand, M., & Stark, K. (2020). Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation, 142(12), 1176–1189. https://doi.org/10.1161/CIRCULATIONAHA.120.048488CrossRefPubMedPubMedCentral

166.

Elajami, T. K., Colas, R. A., Dalli, J., Chiang, N., Serhan, C. N., & Welty, F. K. (2016). Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. The FASEB Journal, 30(8), 2792–2801. https://doi.org/10.1096/fj.201500155RCrossRefPubMedPubMedCentral

167.

Cherpokova, D., Jouvene, C. C., Libreros, S., DeRoo, E. P., Chu, L., de la Rosa, X., & Serhan, C. N. (2019). Resolvin D4 attenuates the severity of pathological thrombosis in mice. Blood, 134(17), 1458–1468. https://doi.org/10.1182/blood.2018886317CrossRefPubMedPubMedCentral

168.

Figliozzi S, Masci PG, Ahmadi N, Tondi L, Koutli E, Aimo A, Georgiopoulos G (2020). Predictors of adverse prognosis in COVID‐19: A systematic review and meta‐analysis. European Journal of Clinical Investigation, 50(10). https://doi.org/10.1111/eci.13362

169.

Pal, A., Gowdy, K. M., Oestreich, K. J., Beck, M., & Shaikh, S. R. (2020). Obesity-driven deficiencies of specialized pro-resolving mediators may drive adverse outcomes during SARS-CoV-2 infection. Frontiers in Immunology, 11, 1997. https://doi.org/10.3389/fimmu.2020.01997CrossRefPubMedPubMedCentral

170.

Neuhofer, A., Zeyda, M., Mascher, D., Itariu, B. K., Murano, I., Leitner, L., & Stulnig, T. M. (2013). Impaired local production of proresolving lipid mediators in obesity and 17-HDHA as a potential treatment for obesity-associated inflammation. Diabetes, 62(6), 1945–1956. https://doi.org/10.2337/db12-0828CrossRefPubMedPubMedCentral

171.

Croasdell, A., Thatcher, T. H., Kottmann, R. M., Colas, R. A., Dalli, J., Serhan, C. N., & Phipps, R. P. (2015). Resolvins attenuate inflammation and promote resolution in cigarette smoke-exposed human macrophages. American Journal of Physiology. Lung Cellular and Molecular Physiology, 309(8), L888-901. https://doi.org/10.1152/ajplung.00125.2015CrossRefPubMedPubMedCentral

172.

Polus, A., Zapala, B., Razny, U., Gielicz, A., Kiec-Wilk, B., Malczewska-Malec, M., & Dembinska-Kiec, A. (2016). Omega-3 fatty acid supplementation influences the whole blood transcriptome in women with obesity, associated with pro-resolving lipid mediator production. Biochimica et Biophysica Acta, 1861(11), 1746–1755. https://doi.org/10.1016/j.bbalip.2016.08.005CrossRefPubMed

173.

Torrinhas, R. S., Calder, P. C., Lemos, G. O., & Waitzberg, D. L. (2021). Parenteral fish oil: An adjuvant pharmacotherapy for coronavirus disease 2019? Nutrition, 81, 110900. https://doi.org/10.1016/j.nut.2020.110900CrossRefPubMed

174.

Torrinhas, R. S., Calder, P. C., & Waitzberg, D. L. (2020). Response to Bistrian BR. Parenteral fish-oil emulsions in critically ill COVID-19 emulsions. JPEN J Parenter Enteral Nutr, 44(7), 1169–1170.CrossRefPubMed

175.

Rogero, M. M., Leao, M. C., Santana, T. M., Pimentel, M., Carlini, G. C. G., da Silveira, T. F. F., & Castro, I. A. (2020). Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19. Free Radical Biology & Medicine, 156, 190–199. https://doi.org/10.1016/j.freeradbiomed.2020.07.005CrossRef

176.

Simopoulos, A. P., Serhan, C. N., & Bazinet, R. P. (2021). The need for precision nutrition, genetic variation and resolution in Covid-19 patients. Molecular Aspects of Medicine, 77, 100943. https://doi.org/10.1016/j.mam.2021.100943CrossRefPubMedPubMedCentral

177.

Souza, P. R., Marques, R. M., Gomez, E. A., Colas, R. A., De Matteis, R., Zak, A., & Dalli, J. (2020). Enriched marine oil supplements increase peripheral blood specialized pro-resolving mediators concentrations and reprogram host immune responses: A randomized double-blind placebo-controlled study. Circulation Research, 126(1), 75–90. https://doi.org/10.1161/CIRCRESAHA.119.315506CrossRefPubMed

178.

Panigrahy, D., Gartung, A., Yang, J., Yang, H., Gilligan, M. M., Sulciner, M. L., & Sukhatme, V. P. (2019). Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. The Journal of Clinical Investigation, 129(7), 2964–2979. https://doi.org/10.1172/JCI127282CrossRefPubMedPubMedCentral

179.

Serhan, C. N., Chiang, N., & Dalli, J. (2018). New pro-resolving n-3 mediators bridge resolution of infectious inflammation to tissue regeneration. Molecular Aspects of Medicine, 64, 1–17. https://doi.org/10.1016/j.mam.2017.08.002CrossRefPubMed

180.

Walker, K. H., Krishnamoorthy, N., Brüggemann, T. R., Shay, A. E., Serhan, C. N., & Levy, B. D. (2021). Protectins PCTR1 and PD1 reduce viral load and lung inflammation during respiratory syncytial virus infection in mice. Frontiers in Immunology, 12, 704427. https://doi.org/10.3389/fimmu.2021.704427CrossRefPubMedPubMedCentral

181.

Lee, C. H. (2021). Role of specialized pro-resolving lipid mediators and their receptors in virus infection: A promising therapeutic strategy for SARS-CoV-2 cytokine storm. Archives of Pharmacal Research, 44(1), 84–98. https://doi.org/10.1007/s12272-020-01299-yCrossRefPubMedPubMedCentral

182.

Sousa, L. P., Pinho, V., & Teixeira, M. M. (2020). Harnessing inflammation resolving-based therapeutic agents to treat pulmonary viral infections: What can the future offer to COVID-19? British Journal of Pharmacology, 177(17), 3898–3904. https://doi.org/10.1111/bph.15164CrossRefPubMedPubMedCentral

183.

Balta, M. G., Papathanasiou, E., & Christopoulos, P. F. (2021). Specialized pro-resolving mediators as potential regulators of inflammatory macrophage responses in COVID-19. Frontiers in Immunology, 12, 632238. https://doi.org/10.3389/fimmu.2021.632238CrossRefPubMedPubMedCentral

184.

Wu, S. H., Chen, X. Q., Liu, B., Wu, H. J., & Dong, L. (2013). Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. British Journal of Dermatology, 168(1), 172–178. https://doi.org/10.1111/j.1365-2133.2012.11177.xCrossRefPubMed

185.

Christie, P. E., Spur, B. W., & Lee, T. H. (1992). The effects of lipoxin A4 on airway responses in asthmatic subjects. The American Review of Respiratory Disease, 145(6), 1281–1284. https://doi.org/10.1164/ajrccm/145.6.1281CrossRefPubMed

186.

Schwarz B, Sharma L, Roberts L, Peng X, Bermejo S, Leighton I, Bosio CM (2020). Severe SARS-CoV-2 infection in humans is defined by a shift in the serum lipidome resulting in dysregulation of eicosanoid immune mediators. Res Sq. https://doi.org/10.21203/rs.3.rs-42999/v1

Title: COVID-19 and cancer: start the resolution!
Authors: Chantal Barksdale
Franciele C. Kipper
Shreya Tripathy
Selvakumar Subbian
Charles N. Serhan
Dipak Panigrahy
Publication date: 01-03-2022
Publisher: Springer US
Keywords: SARS-CoV-2
COVID-19
Cytokines
Published in: Cancer and Metastasis Reviews / Issue 1/2022
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-021-10017-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2022

Anti-HER2 therapy in metastatic breast cancer: many choices and future directions

Adipocytokines and disease progression in endometrial cancer: a systematic review

The emerging roles of circular RNAs in vessel co-option and vasculogenic mimicry: clinical insights for anti-angiogenic therapy in cancers

Glycosylation as a regulator of site-specific metastasis

Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology

Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective

Keynote webinar | Spotlight on antibody–drug conjugates in cancer